Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment

Endocrine-Related Cancer

Volumn 20, Issue 5, 2013, Pages

  Brennen, W Nathaniel ^a   Denmeade, Samuel R ^a   Isaacs, John T ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Inflammation; Mesenchymal stem cell; MSC; Multipotent stromal cell; Prostate cancer

Indexed keywords

5' NUCLEOTIDASE; ENDOGLIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTAGLANDIN; RANTES; SCATTER FACTOR; STROMAL CELL DERIVED FACTOR 1; THY 1 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ADAPTIVE IMMUNITY; ANGIOGENESIS; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL ACTIVITY; CELL DIFFERENTIATION; CELL ISOLATION; CELL LINEAGE; CELL MIGRATION; CHRONIC INFLAMMATION; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; INNATE IMMUNITY; MALIGNANT TRANSFORMATION; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; METASTASIS; METASTASIS POTENTIAL; MULTIPOTENT STEM CELL; NONHUMAN; PROSTATE CANCER; PROSTATE CARCINOGENESIS; PROSTATE HYPERTROPHY; REVIEW; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

EID: 84886383331     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0151     Document Type: Review

References (209)

1. Afizah H, Yang Z, Hui JH, Ouyang HW & Lee EH 2007 A comparison between the chondrogenic potential of human bone marrow stem cells (BMSCs) and adipose-derived stem cells (ADSCs) taken from the same donors. Tissue Engineering 13 659-666. (doi:10.1089/ten.2006.0118)
2. Aggarwal S & PittengerMF 2005 Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105 1815-1822. (doi:10.1182/ blood-2004-04-1559)
3. Allers C, Sierralta WD, Neubauer S, Rivera F, Minguell JJ & Conget PA 2004 Dynamic of distribution of human bone marrow-derived mesenchymal stem cells after transplantation into adult unconditioned mice. Transplantation 78 503-508. (doi:10.1097/01.TP. 0000128334.93343.B3)
4. Ankrum J & Karp JM 2010 Mesenchymal stem cell therapy: two steps forward, one step back. Trends in Molecular Medicine 16 203-209. (doi:10.1016/j.molmed.2010.02.005)
5. Augello A, Tasso R, Negrini SM, Amateis A, Indiveri F, Cancedda R & Pennesi G 2005 Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. European Journal of Immunology 35 1482-1490. (doi:10.1002/ eji.200425405)
6. von Bahr L, Batsis I, Moll G, Hagg M, Szakos A, Sundberg B, Uzunel M, Ringden O & Le Blanc K 2012 Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells 30 1575-1578. (doi:10.1002/stem.1118)
7. Barry FP, Murphy JM, English K & Mahon BP 2005 Immunogenicity of adult mesenchymal stem cells: lessons from the fetal allograft. Stem Cells and Development 14 252-265. (doi:10.1089/scd.2005.14.252)
8. Bergfeld SA & DeClerck YA 2010 Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Reviews 29 249-261. (doi:10.1007/s10555-010-9222-7)
9. Berry SJ, Coffey DS,Walsh PC & Ewing LL 1984 The development of human benign prostatic hyperplasia with age. Journal of Urology 132 474-479. (doi:10.1242/jcs.02511)
10. Bertani N, Malatesta P, Volpi G, Sonego P & Perris R 2005 Neurogenic potential of human mesenchymal stem cells revisited: analysis by immunostaining, time-lapse video and microarray. Journal of Cell Science 118 3925-3936. (doi:10.1242/jcs.02511)
11. Beyth S, Borovsky Z,Mevorach D, Liebergall M, Gazit Z, Aslan H, Galun E & Rachmilewitz J 2005 Human mesenchymal stem cells alter antigenpresenting cell maturation and induce T-cell unresponsiveness. Blood 105 2214-2219. (doi:10.1182/blood-2004-07-2921)
12. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG & Moses HL 2004 TGF-b signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303 848-851. (doi:10.1126/science.1090922)
13. Bianchi G, Borgonovo G, Pistoia V & Raffaghello L 2011 Immunosuppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cells. Histology and Histopathology 26 941-951.
14. Bianco P, Robey PG & Simmons PJ 2008 Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell 2 313-319. (doi:10.1016/j. stem.2008.03.002)
15. Bissell MJ & Hines WC 2011 Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression Nature Medicine 17 320-329. (doi:10.1038/nm.2328)
16. Blasi A, Martino C, Balducci L, Saldarelli M, Soleti A, Navone SE, Canzi L, Cristini S, Invernici G, Parati EA et al. 2011 Dermal fibroblasts display similar phenotypic and differentiation capacity to fat-derived mesenchymal stem cells, but differ in anti-inflammatory and angiogenic potential. Vascular Cell 3 5. (doi:10.1186/2045-824X-3-5)
17. Bocelli-Tyndall C, Bracci L, Schaeren S, Feder-Mengus C, Barbero A, Tyndall A & Spagnoli GC 2009 Human bone marrow mesenchymal stem cells and chondrocytes promote and/or suppress the in vitro proliferation of lymphocytes stimulated by interleukins 2, 7 and 15. Annals of the Rheumatic Diseases 68 1352-1359. (doi:10.1136/ard.2008.094003)
18. Borghese C, Cattaruzza L, Pivetta E, Normanno N, De Luca A, Mazzucato M, Celegato M, Colombatti A & Aldinucci D 2012 Gefitinib inhibits the cross-talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity. Journal of Cellular Biochemistry 114 1135-1144. (doi:10.1002/jcb.24456)
19. Brennen WN, Isaacs JT & Denmeade SR 2012 Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Molecular Cancer Therapeutics 11 257-266. (doi:10.1158/1535-7163.MCT-11-0340)
20. Brennen WN, Chen S, Denmeade SR & Isaacs JT 2013 Quantification of mesenchymal stem cells (MSCs) at sites of human prostate cancer. Oncotarget 4 106-117.
21. Brohlin M, Kingham PJ, Novikova LN, Novikov LN &WibergM2012 Aging effect on neurotrophic activity of human mesenchymal stem cells. PLoS ONE 7 e45052. (doi:10.1371/journal.pone.0045052)
22. Brown JM, Nemeth K, Kushnir-Sukhov NM, Metcalfe DD & Mezey E 2011 Bone marrow stromal cells inhibit mast cell function via a COX2- dependent mechanism. Clinical and Experimental Allergy 41 526-534. (doi:10.1111/j.1365- 2222.2010.03685.x)
23. Caplan AI 1991 Mesenchymal stem cells. Journal of Orthopaedic Research 9 641-650. (doi:10.1002/jor.1100090504)
24. Caplan AI 2009 Why are MSCs therapeutic? New data: new insight Journal of Pathology 217 318-324. (doi:10.1002/path.2469)
25. Cavarretta IT, Altanerova V, Matuskova M, Kucerova L, Culig Z & Altaner C 2010 Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth. Molecular Therapy 18 223-231. (doi:10.1038/mt.2009.237)
26. Chan JL, Tang KC, Patel AP, Bonilla LM, Pierobon N, Ponzio NM & Rameshwar P 2006 Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-g. Blood 107 4817-4824. (doi:10.1182/blood-2006-01-0057)
27. Chanda D, Isayeva T, Kumar S, Hensel JA, Sawant A, Ramaswamy G, Siegal GP, Beatty MS & Ponnazhagan S 2009 Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in prostate cancer bone metastasis. Clinical Cancer Research 15 7175-7185. (doi:10.1158/ 1078-0432.CCR-09-1938)
28. Choi KS, Ahn SY, Kim TS, Kim J, Kim BG, Han KH, Ban SJ, Kim HS, Choi Y & Lim CJ 2011 Characterization and biodistribution of human mesenchymal stem cells transduced with lentiviral-mediated BMP2. Archives of Pharmacal Research 34 599-606. (doi:10.1007/s12272-011- 0410-y)
29. Choi SA, Lee JY,Wang KC, Phi JH, Song SH, Song J & Kim SK 2012 Human adipose tissue-derived mesenchymal stem cells: characteristics and therapeutic potential as cellular vehicles for prodrug gene therapy against brainstem gliomas. European Journal of Cancer 48 129-137. (doi:10.1016/j.ejca.2011.04.033)
30. Chung LW 1991 Fibroblasts are critical determinants in prostatic cancer growth and dissemination. Cancer Metastasis Reviews 10 263-274. (doi:10.1007/BF00050797)
31. Ciavarella S, Dominici M, Dammacco F & Silvestris F 2011 Mesenchymal stem cells: a new promise in anticancer therapy. Stem Cells and Development 20 1-10. (doi:10.1089/scd.2010.0223)
32. Clouston D & Bolton D 2012 In situ and intraductal epithelial proliferations of prostate: definitions and treatment implications. Part 1: prostatic intraepithelial neoplasia. BJU International 109 (Suppl 3) 22-26. (doi:10.1111/j.1464-410X.2012.11040.x)
33. Coffelt SB,Marini FC, Watson K, Zwezdaryk KJ, Dembinski JL, LaMarca HL, Tomchuck SL, Honer zu Bentrup K, Danka ES, Henkle SL et al. 2009 The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. PNAS 106 3806-3811. (doi:10.1073/pnas.0900244106)
34. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, Risso M, Gualandi F, Mancardi GL, Pistoia V et al. 2006 Human mesenchymal stem cells modulate B-cell functions. Blood 107 367-372. (doi:10.1182/blood-2005-07- 2657)
35. Correia AL & Bissell MJ 2012 The tumor microenvironment is a dominant force in multidrug resistance. Drug Resistance Updates 15 39-49. (doi:10.1016/j.drup.2012.01.006)
36. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, Andriolo G, Sun B, Zheng B, Zhang L et al. 2008 A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3 301-313. (doi:10.1016/j.stem. 2008.07.003)
37. Cunha GR, Hayward SW, Wang YZ & Ricke WA 2003 Role of the stromal microenvironment in carcinogenesis of the prostate. International Journal of Cancer 107 1-10. (doi:10.1002/ijc.11335)
38. Davani B, Ikonomou L, Raaka BM, Geras-Raaka E, Morton RA, Marcus-Samuels B & Gershengorn MC 2007 Human islet-derived precursor cells are mesenchymal stromal cells that differentiate and mature to hormone-expressing cells in vivo. Stem Cells 25 3215-3222. (doi:10.1634/stemcells.2007-0323)
39. Dayyani F, Gallick GE, Logothetis CJ & Corn PG 2011 Novel therapies for metastatic castrate-resistant prostate cancer. Journal of the National Cancer Institute 103 1665-1675. (doi:10.1093/jnci/djr362)
40. Delongchamps NB, Singh A & Haas GP 2006 The role of prevalence in the diagnosis of prostate cancer. Cancer Control 13 158-168.
41. De Marzo AM, Marchi VL, Epstein JI & Nelson WG 1999 Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. American Journal of Pathology 155 1985-1992. (doi:10.1016/S0002-9440(10) 65517-4)
42. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, IsaacsWB & NelsonWG 2007 Inflammation in prostate carcinogenesis. Nature Reviews. Cancer 7 256-269. (doi:10.1038/nrc2090)
43. Dembinski JL, Spaeth EL, Fueyo J, Gomez-Manzano C, Studeny M, Andreeff M & Marini FC 2010 Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells. Cancer Gene Therapy 17 289-297. (doi:10.1038/cgt.2009. 67)
44. Denmeade SR, Jakobsen CM, Janssen S, Khan SR, Garrett ES, Lilja H, Christensen SB & Isaacs JT 2003 Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. Journal of the National Cancer Institute 95 990-1000. (doi:10.1093/jnci/95.13.990)
45. De Nunzio C, Kramer G, Marberger M, Montironi R, NelsonW, Schroder F, Sciarra A & Tubaro A 2011 The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. European Urology 60 106-117. (doi:10.1016/j.eururo. 2011.03.055)
46. De Ugarte DA, Morizono K, Elbarbary A, Alfonso Z, Zuk PA, Zhu M, Dragoo JL, Ashjian P, Thomas B, Benhaim P et al. 2003 Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells, Tissues, Organs 174 101-109. (doi:10.1159/000071150)
47. Detante O, Moisan A, Dimastromatteo J, Richard MJ, Riou L, Grillon E, Barbier E, Desruet MD, De Fraipont F, Segebarth C et al. 2009 Intravenous administration of 99mTc-HMPAO-labeled human mesenchymal stem cells after stroke: in vivo imaging and biodistribution. Cell Transplantation 18 1369-1379. (doi:10.3727/ 096368909X474230)
48. Devine SM, Cobbs C, Jennings M, Bartholomew A & Hoffman R 2003 Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 101 2999-3001. (doi:10.1182/blood-2002- 06-1830)
49. Djouad F, Charbonnier LM, Bouffi C, Louis-Plence P, Bony C, Apparailly F, Cantos C, Jorgensen C & Noel D 2007 Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 25 2025-2032. (doi:10.1634/stemcells. 2006-0548)
50. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D & Horwitz E 2006 Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8 315-317. (doi:10.1080/ 14653240600855905)
51. Duan X, Guan H, Cao Y & Kleinerman ES 2009 Murine bone marrowderived mesenchymal stem cells as vehicles for interleukin-12 gene delivery into Ewing sarcoma tumors. Cancer 115 13-22. (doi:10.1002/ cncr.24013)
52. van Eekelen M, Sasportas LS, Kasmieh R, Yip S, Figueiredo JL, Louis DN, Weissleder R & Shah K 2010 Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors. Oncogene 29 3185-3195. (doi:10.1038/onc.2010.75)
53. Eliopoulos N, Stagg J, Lejeune L, Pommey S & Galipeau J 2005 Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood 106 4057-4065. (doi:10.1182/ blood-2005-03-1004)
54. Elzaouk L, Moelling K & Pavlovic J 2006 Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model. Experimental Dermatology 15 865-874. (doi:10.1111/j.1600-0625.2006. 00479.x)
55. English K & Mahon BP 2011 Allogeneic mesenchymal stem cells: agents of immune modulation. Journal of Cellular Biochemistry 112 1963-1968. (doi:10.1002/jcb.23119)
56. English K, Barry FP, Field-Corbett CP & Mahon BP 2007 IFN-g and TNF-a differentially regulate immunomodulation by murine mesenchymal stem cells. Immunology Letters 110 91-100. (doi:10.1016/j.imlet.2007. 04.001)
57. Franco OE, Shaw AK, Strand DW & Hayward SW 2010 Cancer associated fibroblasts in cancer pathogenesis. Seminars in Cell & Developmental Biology 21 33-39. (doi:10.1016/j.semcdb.2009.10.010)
58. Friedenstein AJ, Chailakhjan RK & Lalykina KS 1970 The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell and Tissue Kinetics 3 393-403. (doi:10.1111/j.1365- 2184.1970.tb00347.x)
59. Friedenstein AJ, Gorskaja JF & Kulagina NN 1976 Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Experimental Hematology 4 267-274.
60. Fritz V, Noel D, Bouquet C, Opolon P, Voide R, Apparailly F, Louis-Plence P, Bouffi C, Drissi H, Xie C et al. 2008 Antitumoral activity and osteogenic potential of mesenchymal stem cells expressing the urokinase-type plasminogen antagonist amino-terminal fragment in a murine model of osteolytic tumor. Stem Cells 26 2981-2990. (doi:10.1634/stemcells. 2008-0139)
61. Fritz V, Brondello JM, Gordeladze JO, Reseland JE, Bony C, Yssel H, Noel D & Jorgensen C 2011 Bone-metastatic prostate carcinoma favors mesenchymal stem cell differentiation toward osteoblasts and reduces their osteoclastogenic potential. Journal of Cellular Biochemistry 112 3234-3245. (doi:10.1002/jcb. 23258)
62. Fujita K, Ewing CM, Getzenberg RH, Parsons JK, Isaacs WB & Pavlovich CP 2010 Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia. Prostate 70 473-481. (doi:10.1002/pros.21081)
63. Gao J, Dennis JE, Muzic RF, Lundberg M & Caplan AI 2001 The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells, Tissues, Organs 169 12-20. (doi:10.1159/ 000047856)
64. Gao P, Ding Q, Wu Z, Jiang H & Fang Z 2010 Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma. Cancer Letters 290 157-166. (doi:10.1016/j.canlet.2009.08.031)
65. Garcia S, Bernad A, Martin MC, Cigudosa JC, Garcia-Castro J & de la Fuente R 2010 Pitfalls in spontaneous in vitro transformation of human mesenchymal stem cells. Experimental Cell Research 316 1648-1650. (doi:10.1016/j.yexcr.2010.02.016)
66. Garcia-Gomez I, Elvira G, Zapata AG, Lamana ML, Ramirez M, Castro JG, Arranz MG, Vicente A, Bueren J & Garcia-Olmo D 2010 Mesenchymal stem cells: biological properties and clinical applications. Expert Opinion on Biological Therapy 10 1453-1468. (doi:10.1517/14712598.2010. 519333)
67. Giannoni E, Bianchini F, Masieri L, Serni S, Torre E, Calorini L & Chiarugi P 2010 Reciprocal activation of prostate cancer cells and cancerassociated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Research 70 6945-6956. (doi:10.1158/ 0008-5472.CAN-10-0785)
68. Grisendi G, Bussolari R, Cafarelli L, Petak I, Rasini V,Veronesi E, De Santis G, Spano C, Tagliazzucchi M, Barti-Juhasz H et al. 2010 Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Research 70 3718-3729. (doi:10.1158/0008-5472.CAN-09-1865)
69. Gunnarsson S, Bexell D, Svensson A, Siesjo P, Darabi A & Bengzon J 2010 Intratumoral IL-7 delivery by mesenchymal stromal cells potentiates IFNgamma-transduced tumor cell immunotherapy of experimental glioma. Journal of Neuroimmunology 218 140-144. (doi:10.1016/j. jneuroim.2009.10.017)
70. Hanahan D & Weinberg RA 2011 Hallmarks of cancer: the next generation. Cell 144 646-674. (doi:10.1016/j.cell.2011.02.013)
71. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS et al. 2009 A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. Journal of the American College of Cardiology 54 2277-2286. (doi:10.1016/j.jacc. 2009.06.055)
72. Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, Tracy M, Ghersin E, Johnston PV, Brinker JA et al. 2012 Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. Journal of the American Medical Association 308 2369-2379. (doi:10.1001/jama.2012.25321)
73. Hermann A, List C, Habisch HJ, Vukicevic V, Ehrhart-Bornstein M, Brenner R, Bernstein P, Fickert S & Storch A 2010 Age-dependent neuroectodermal differentiation capacity of human mesenchymal stromal cells: limitations for autologous cell replacement strategies. Cytotherapy 12 17-30. (doi:10.3109/14653240903313941)
74. Hirschi KK & D'Amore PA 1996 Pericytes in the microvasculature. Cardiovascular Research 32 687-698. (doi:10.1016/S0008-6363(96) 00063-6)
75. Ho AD, Wagner W & Franke W 2008 Heterogeneity of mesenchymal stromal cell preparations. Cytotherapy 10 320-330. (doi:10.1080/ 14653240802217011)
76. Hofstetter CP, Schwarz EJ, Hess D, Widenfalk J, El Manira A, Prockop DJ & Olson L 2002 Marrow stromal cells form guiding strands in the injured spinal cord and promote recovery. PNAS 99 2199-2204. (doi:10.1073/ pnas.042678299)
77. Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC, Deans RJ, Krause DS & Keating A 2005 Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 7 393-395. (doi:10.1080/ 14653240500319234)
78. Huang JI, Kazmi N, Durbhakula MM, Hering TM, Yoo JU & Johnstone B 2005 Chondrogenic potential of progenitor cells derived from human bone marrow and adipose tissue: a patient-matched comparison. Journal of Orthopaedic Research 23 1383-1389.
79. Huang XP, Sun Z, Miyagi Y, McDonald Kinkaid H, Zhang L, Weisel RD & Li RK 2010 Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation 122 2419-2429. (doi:10.1161/CIRCULATIONAHA. 110.955971)
80. Huang YF, Chen MJ,Wu MH & Hung SC 2013 The use of hypoxic cultured mesenchymal stem cell for oncolytic virus therapy. Cancer Gene Therapy 20 308-316. (doi:10.1038/cgt.2013.22)
81. Iso Y, Spees JL, Serrano C, Bakondi B, Pochampally R, Song YH, Sobel BE, Delafontaine P & Prockop DJ 2007 Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment. Biochemical and Biophysical Research Communications 354 700-706. (doi:10.1016/j.bbrc.2007.01.045)
82. Jackson CM, Flies DB, Mosse CA, Parwani A, Hipkiss EL & Drake CG 2012 Strain-specific induction of experimental autoimmune prostatitis (EAP) in mice. Prostate 73 651-656. (doi:10.1002/pros.22606)
83. Jansen BJ, Gilissen C, Roelofs H, Schaap-Oziemlak A, Veltman JA, Raymakers RA, Jansen JH, Kogler G, Figdor CG, Torensma R et al. 2010 Functional differences betweenmesenchymal stem cell populations are reflected by their transcriptome. Stem Cells and Development 19 481-490. (doi:10.1089/scd.2009. 0288)
84. Jiang R, Han Z, Zhuo G, Qu X, Li X, Wang X, Shao Y, Yang S & Han ZC 2011 Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study. Frontiers of Medicine 5 94-100. (doi:10.1007/ s11684-011-0116-z)
85. Jung Y, Kim JK, Shiozawa Y, Wang J, Mishra A, Joseph J, Berry JE, McGee S, Lee E, Sun H et al. 2013 Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nature Communications 4 1795. (doi:10.1038/ ncomms2766)
86. Kalluri R & Zeisberg M 2006 Fibroblasts in cancer. Nature Reviews. Cancer 6 392-401. (doi:10.1038/nrc1877)
87. Kanehira M, Xin H, Hoshino K, Maemondo M, Mizuguchi H, Hayakawa T, Matsumoto K, Nakamura T, Nukiwa T & Saijo Y 2007 Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cells. Cancer Gene Therapy 14 894-903. (doi:10.1038/sj.cgt.7701079)
88. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R & Weinberg RA 2007 Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449 557-563. (doi:10.1038/nature06188)
89. Kassis I, Zangi L, Rivkin R, Levdansky L, Samuel S, Marx G & Gorodetsky R 2006 Isolation of mesenchymal stem cells from G-CSF-mobilized human peripheral blood using fibrin microbeads. Bone Marrow Transplantation 37 967-976. (doi:10.1038/sj.bmt.1705358)
90. Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II, Nguyen AT, Malide D, Combs CA, Hall G et al. 2006 Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. Journal of Experimental Medicine 203 1235-1247. (doi:10.1084/ jem.20051921)
91. Kidd S, Caldwell L, Dietrich M, Samudio I, Spaeth EL, Watson K, Shi Y, Abbruzzese J, Konopleva M, Andreeff M et al. 2010 Mesenchymal stromal cells alone or expressing interferon-b suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy 12 615-625. (doi:10.3109/14653241003631815)
92. Kidd S, Spaeth E, Watson K, Burks J, Lu H, Klopp A, AndreeffM& Marini FC 2012 Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS ONE 7 e30563. (doi:10.1371/journal.pone.0030563)
93. Klopp AH, Gupta A, Spaeth E, Andreeff M & Marini F III 2011 Concise review: dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells 29 11-19. (doi:10.1002/stem.559)
94. Knoop K, Kolokythas M, Klutz K, Willhauck MJ, Wunderlich N, Draganovici D, Zach C, Gildehaus FJ, Boning G, Goke B et al. 2011 Image-guided, tumor stroma-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated NIS gene delivery. Molecular Therapy 19 1704-1713. (doi:10.1038/mt.2011.93)
95. Komarova S, Kawakami Y, Stoff-Khalili MA, Curiel DT & Pereboeva L 2006 Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Molecular Cancer Therapeutics 5 755-766. (doi:10.1158/1535-7163. MCT-05-0334)
96. Kramer G, Mitteregger D & Marberger M 2007 Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? European Urology 51 1202-1216. (doi:10.1016/j.eururo.2006.12.011)
97. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E & Dazzi F 2003 Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101 3722-3729. (doi:10.1182/blood-2002-07-2104)
98. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, Santarlasci V, Mazzinghi B, Pizzolo G, Vinante F et al. 2006 Role for interferon-g in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24 386-398. (doi:10.1634/stemcells.2005-0008)
99. Krampera M, Marconi S, Pasini A, Galie M, Rigotti G, Mosna F, Tinelli M, Lovato L, Anghileri E, Andreini A et al. 2007 Induction of neural-like differentiation in human mesenchymal stem cells derived from bone marrow, fat, spleen and thymus. Bone 40 382-390. (doi:10.1016/j.bone. 2006.09.006)
100. Krasnodembskaya A, Song Y, Fang X, Gupta N, Serikov V, Lee JW & Matthay MA 2010 Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells 28 2229-2238. (doi:10.1002/stem.544)
101. Kucerova L, Altanerova V, Matuskova M, Tyciakova S & Altaner C 2007 Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Research 67 6304-6313. (doi:10.1158/0008-5472.CAN-06-4024)
102. Kucerova L, Matuskova M, Pastorakova A, Tyciakova S, Jakubikova J, Bohovic R, Altanerova V & Altaner C 2008 Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice. Journal of Gene Medicine 10 1071-1082. (doi:10.1002/jgm.1239)
103. La Gruta NL, Kedzierska K, Stambas J & Doherty PC 2007 A question of self-preservation: immunopathology in influenza virus infection. Immunology and Cell Biology 85 85-92. (doi:10.1038/sj.icb.7100026)
104. Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, Granton J & Stewart DJ 2012 Safety of cell therapy with mesenchymal stromal cells (SafeCell) : a systematic review and meta-analysis of clinical trials. PLoS ONE 7 e47559. (doi:10.1371/journal.pone.0047559)
105. Lama VN, Smith L, Badri L, Flint A, Andrei AC, Murray S, Wang Z, Liao H, Toews GB, Krebsbach PH et al. 2007 Evidence for tissue-resident mesenchymal stem cells in human adult lung from studies of transplanted allografts. Journal of Clinical Investigation 117 989-996. (doi:10.1172/JCI29713)
106. Lanzoni G, Alviano F, Marchionni C, Bonsi L, Costa R, Foroni L, Roda G, Belluzzi A, Caponi A, Ricci F et al. 2009 Isolation of stem cell populations with trophic and immunoregulatory functions from human intestinal tissues: potential for cell therapy in inflammatory bowel disease. Cytotherapy 11 1020-1031. (doi:10.3109/ 14653240903253840)
107. Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ, McCarthy P, Atkinson K, Cooper BW et al. 2005 Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biology of Blood and Marrow Transplantation 11 389-398. (doi:10.1016/j.bbmt.2005.02.001)
108. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E & Ringden O 2003a HLA expression and immunologic properties of differentiated and undifferentiatedmesenchymal stem cells. Experimental Hematology 31 890-896. (doi:10.1016/S0301-472X(03) 00110-3)
109. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE & Ringden O 2003b Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scandinavian Journal of Immunology 57 11-20. (doi:10.1046/j.1365-3083.2003. 01176.x)
110. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M & Ringden O 2004 Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363 1439-1441. (doi:10.1016/S0140-6736(04) 16104-7)
111. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M et al. 2008 Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371 1579-1586. (doi:10.1016/S0140- 6736(08) 60690-X)
112. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, Semprun-Prieto L, Delafontaine P & Prockop DJ 2009 Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 5 54-63. (doi:10.1016/j.stem. 2009.05.003)
113. Lee CH, Shah B, Moioli EK & Mao JJ 2010 CTGF directs fibroblast differentiation from human mesenchymal stem/stromal cells and defines connective tissue healing in a rodent injury model. Journal of Clinical Investigation 120 3340-3349. (doi:10.1172/JCI43230)
114. Lee MJ, Heo SC, Shin SH, Kwon YW, Do EK, Suh DS, Yoon MS & Kim JH 2013 OncostatinMpromotes mesenchymal stem cell-stimulated tumor growth through a paracrine mechanism involving periostin and Betaig-h3. International Journal of Biochemistry & Cell Biology 45 1869-1877. (doi:10.1016/j.biocel.2013.05. 027)
115. Li Y & Lin F 2012 Mesenchymal stem cells are injured by complement after their contact with serum. Blood 120 3436-3443. (doi:10.1182/blood- 2012-03-420612)
116. Li X, Sterling JA, Fan KH, Vessella RL, Shyr Y, Hayward SW, Matrisian LM& Bhowmick NA 2012 Loss of TGF-b responsiveness in prostate stromal cells alters chemokine levels and facilitates the development of mixed osteoblastic/osteolytic bone lesions. Molecular Cancer Research 10 494-503. (doi:10.1158/1541-7786.MCR-11-0506)
117. Li X, Wang D, Liang J, Zhang H & Sun L 2013 Mesenchymal SCT ameliorates refractory cytopenia in patients with systemic lupus erythematosus. Bone Marrow Transplantation 48 544-550. (doi:10.1038/ bmt.2012.184)
118. Lin VK, Wang SY, Vazquez DV, Xu C, Zhang S & Tang L 2007 Prostatic stromal cells derived from benign prostatic hyperplasia specimens possess stem cell like property. Prostate 67 1265-1276. (doi:10.1002/ pros.20599)
119. Lin G, Yang R, Banie L, Wang G, Ning H, Li LC, Lue TF & Lin CS 2010 Effects of transplantation of adipose tissue-derived stem cells on prostate tumor. Prostate 70 1066-1073. (doi:10.1002/pros.21140)
120. Lin P, Lin Y, Lennon DP, Correa D, SchluchterM& Caplan AI 2012 Efficient lentiviral transduction of human mesenchymal stem cells that preserves proliferation and differentiation capabilities. Stem Cells Translational Medicine 1 886-897. (doi:10.5966/sctm.2012-0086)
121. Liotta F, Angeli R, Cosmi L, Fili L, Manuelli C, Frosali F, Mazzinghi B, Maggi L, Pasini A, Lisi V et al. 2008 Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells 26 279-289. (doi:10.1634/stemcells.2007-0454)
122. Liu AY, Roudier MP & True LD 2004 Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. American Journal of Pathology 165 1543-1556. (doi:10.1016/S0002- 9440(10) 63412-8)
123. Liu H, Kemeny DM, Heng BC, Ouyang HW, Melendez AJ & Cao T 2006 The immunogenicity and immunomodulatory function of osteogenic cells differentiated from mesenchymal stem cells. Journal of Immunology 176 2864-2871.
124. Mader EK, Maeyama Y, Lin Y, Butler GW, Russell HM, Galanis E, Russell SJ, Dietz AB & Peng KW 2009 Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clinical Cancer Research 15 7246-7255. (doi:10.1158/1078-0432. CCR-09-1292)
125. Mishra PJ, Humeniuk R, Medina DJ, Alexe G, Mesirov JP, Ganesan S, Glod JW & Banerjee D 2008 Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Research 68 4331-4339. (doi:10.1158/0008- 5472.CAN-08-0943)
126. Mishra PJ, Glod JW& Banerjee D 2009 Mesenchymal stem cells: flip side of the coin. Cancer Research 69 1255-1258. (doi:10.1158/0008-5472.CAN- 08-3562)
127. Morikawa S, Mabuchi Y, Niibe K, Suzuki S, Nagoshi N, Sunabori T, Shimmura S, Nagai Y, Nakagawa T, Okano H et al. 2009 Development of mesenchymal stem cells partially originate from the neural crest. Biochemical and Biophysical Research Communications 379 1114-1119. (doi:10.1016/j.bbrc.2009.01.031)
128. Mougiakakos D, Jitschin R, Johansson CC, Okita R, Kiessling R & Le Blanc K 2011 The impact of inflammatory licensing on heme oxygenase-1- mediated induction of regulatory T cells by human mesenchymal stem cells. Blood 117 4826-4835. (doi:10.1182/blood-2010-12-324038)
129. Musina RA, Bekchanova ES, Belyavskii AV & Sukhikh GT 2006 Differentiation potential of mesenchymal stem cells of different origin. Bulletin of Experimental Biology and Medicine 141 147-151. (doi:10.1007/s10517- 006-0115-2)
130. Nakamura K, Ito Y, Kawano Y, Kurozumi K, Kobune M, Tsuda H, Bizen A, Honmou O, Niitsu Y & Hamada H 2004 Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Therapy 11 1155-1164. (doi:10.1038/sj.gt.3302276)
131. Nakashima H, Kaur B & Chiocca EA 2010 Directing systemic oncolytic viral delivery to tumors via carrier cells. Cytokine & Growth Factor Reviews 21 119-126. (doi:10.1016/j.cytogfr.2010.02.004)
132. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R & Fibbe WE 2006 Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 108 2114-2120. (doi:10.1182/blood- 2005-11-011650)
133. Nelson WG, De Marzo AM & Isaacs WB 2003 Prostate cancer. New England Journal of Medicine 349 366-381. (doi:10.1056/NEJMra021562)
134. Newman RE, Yoo D, LeRoux MA & Danilkovitch-Miagkova A 2009 Treatment of inflammatory diseases with mesenchymal stem cells. Inflammation & Allergy Drug Targets 8 110-123. (doi:10.2174/ 187152809788462635)
135. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC & Rittmaster RS 2008 The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. European Urology 54 1379-1384. (doi:10.1016/j. eururo.2007.11.026)
136. Niemeyer P, Vohrer J, Schmal H, Kasten P, Fellenberg J, Suedkamp NP & Mehlhorn AT 2008 Survival of human mesenchymal stromal cells from bone marrow and adipose tissue after xenogenic transplantation in immunocompetent mice. Cytotherapy 10 784-795. (doi:10.1080/ 14653240802419302)
137. Niess H, Bao Q, Conrad C, Zischek C, Notohamiprodjo M, Schwab F, Schwarz B, Huss R, Jauch KW, Nelson PJ et al. 2011 Selective targeting of genetically engineered mesenchymal stem cells to tumor stroma microenvironments using tissue-specific suicide gene expression suppresses growth of hepatocellular carcinoma. Annals of Surgery 254 767-774; discussion 774-765. (doi:10.1097/SLA.0b013e3182368c4f)
138. Noel D, Caton D, Roche S, Bony C, Lehmann S, Casteilla L, Jorgensen C & Cousin B 2008 Cell specific differences between human adipose-derived and mesenchymal-stromal cells despite similar differentiation potentials. Experimental Cell Research 314 1575-1584. (doi:10.1016/ j.yexcr.2007.12.022)
139. Nombela-Arrieta C, Ritz J & Silberstein LE 2011 The elusive nature and function of mesenchymal stem cells. Nature Reviews. Molecular Cell Biology 12 126-131. (doi:10.1038/nrm3049)
140. Ohlsson LB, Varas L, Kjellman C, Edvardsen K & Lindvall M 2003 Mesenchymal progenitor cell-mediated inhibition of tumor growth in vivo and in vitro in gelatin matrix. Experimental and Molecular Pathology 75 248-255. (doi:10.1016/j.yexmp.2003.06.001)
141. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD & Cunha GR 1999 Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Research 59 5002-5011.
142. Orimo A & Weinberg RA 2006 Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 5 1597-1601. (doi:10.4161/cc.5. 15.3112)
143. Osiris Therapeutics I 2012 World's First Approved Stem Cell Drug; Osiris Receives Marketing Clearance from Health Canada for Prochymal. Ed E Elchin. Columbia, MD. (available at: http://investor.osiris.com/release detail.cfm?ReleaseID=674658)
144. Osterholm MT 2005 Preparing for the next pandemic. New England Journal of Medicine 352 1839-1842. (doi:10.1056/NEJMp058068)
145. Pachon-Pena G, Yu G, Tucker A,Wu X, Vendrell J, Bunnell BA & Gimble JM 2011 Stromal stem cells from adipose tissue and bone marrow of agematched female donors display distinct immunophenotypic profiles. Journal of Cellular Physiology 226 843-851. (doi:10.1002/jcp.22408)
146. Panepucci RA, Siufi JL, Silva WA Jr, Proto-Siquiera R, Neder L, Orellana M, Rocha V, Covas DT & Zago MA 2004 Comparison of gene expression of umbilical cord vein and bone marrow-derived mesenchymal stem cells. Stem Cells 22 1263-1278. (doi:10.1634/stemcells.2004-0024)
147. Park HW, Shin JS & Kim CW 2007 Proteome of mesenchymal stem cells. Proteomics 7 2881-2894. (doi:10.1002/pmic.200700089)
148. Paunescu V, Bojin FM, Tatu CA, Gavriliuc OI, Rosca A, Gruia AT, Tanasie G, Bunu C, Crisnic D, Gherghiceanu M et al. 2011 Tumour-associated fibroblasts and mesenchymal stem cells: more similarities than differences. Journal of Cellular and Molecular Medicine 15 635-646. (doi:10.1111/j.1582-4934.2010.01044. x)
149. Pessina A, Bonomi A, Cocce V, Invernici G, Navone S, Cavicchini L, Sisto F, Ferrari M, Vigano L, Locatelli A et al. 2011 Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy. PLoS ONE 6 e28321. (doi:10.1371/journal.pone.0028321)
150. Pevsner-Fischer M, Morad V, Cohen-Sfady M, Rousso-Noori L, Zanin-Zhorov A, Cohen S, Cohen IR & Zipori D 2007 Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood 109 1422-1432. (doi:10.1182/blood-2006-06-028704)
151. Pevsner-Fischer M, Levin S & Zipori D 2011 The origins of mesenchymal stromal cell heterogeneity. Stem Cell Reviews 7 560-568. (doi:10.1007/ s12015-011-9229-7)
152. Phinney DG & Prockop DJ 2007 Concise review: mesenchymal stem/ multipotent stromal cells: the state of transdifferentiation and modes of tissue repair - current views. Stem Cells 25 2896-2902. (doi:10.1634/ stemcells.2007-0637)
153. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S & Marshak DR 1999 Multilineage potential of adult human mesenchymal stem cells. Science 284 143-147. (doi:10.1126/ science.284.5411.143)
154. Placencio VR, Li X, Sherrill TP, Fritz G & Bhowmick NA 2010 Bone marrow derived mesenchymal stem cells incorporate into the prostate during regrowth. PLoS ONE 5 e12920. (doi:10.1371/journal.pone.0012920)
155. Prantl L, Muehlberg F, Navone NM, Song YH, Vykoukal J, Logothetis CJ & Alt EU 2010 Adipose tissue-derived stem cells promote prostate tumor growth. Prostate 70 1709-1715. (doi:10.1002/pros.21206)
156. Prasad VK, Lucas KG, Kleiner GI, Talano JA, Jacobsohn D, Broadwater G, Monroy R & Kurtzberg J 2011 Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biology of Blood and Marrow Transplantation 17 534-541. (doi:10.1016/j.bbmt.2010.04. 014)
157. PRNewswire 2011 Positive Results from Phase 2 Trial of Mesoblast's Adult Stem Cell Therapy Presented at the American Heart Association Annual Meeting. Orlando, FL and Melbourne, Australia. (available at: www. prnewswire.com/news- releases/positive-results-from-phase-2-trial-ofmesoblasts- adult-stem-cell- therapy-presented-at-the-american-heartassociation- annual-meeting-133835958. html)
158. Prockop DJ 2007 "Stemness", does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCs) Clinical Pharmacology and Therapeutics 82 241-243. (doi:10.1038/sj.clpt.6100313)
159. Prockop DJ 2013 Two negative feedback loops place mesenchymal stem/stromal cells (MSCs) at the center of early regulators of inflammation. Stem Cells [in press]. (doi:10.1002/stem.1400)
160. Prockop DJ & Oh JY 2012 Mesenchymal stem/stromal cells (MSCs) : role as guardians of inflammation. Molecular Therapy 20 14-20. (doi:10.1038/ mt.2011.211)
161. Qiao L, Xu Z, Zhao T, Zhao Z, Shi M, Zhao RC, Ye L & Zhang X 2008 Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Research 18 500-507. (doi:10.1038/cr.2008.40)
162. Rada T, Reis RL & Gomes ME 2011 Distinct stem cells subpopulations isolated from human adipose tissue exhibit different chondrogenic and osteogenic differentiation potential. Stem Cell Reviews 7 64-76. (doi:10.1007/s12015-010- 9147-0)
163. Rasmusson I, Ringden O, Sundberg B & Le Blanc K 2005 Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Experimental Cell Research 305 33-41. (doi:10.1016/j. yexcr.2004.12.013)
164. Ren C, Kumar S, Chanda D, Kallman L, Chen J, Mountz JD & Ponnazhagan S 2008a Cancer gene therapy using mesenchymal stem cells expressing interferon-b in a mouse prostate cancer lung metastasis model. Gene Therapy 15 1446-1453. (doi:10.1038/gt.2008.101)
165. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, Zhao RC & Shi Y 2008b Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2 141-150. (doi:10.1016/j.stem.2007.11.014)
166. Sakaguchi Y, Sekiya I, Yagishita K & Muneta T 2005 Comparison of human stem cells derived from various mesenchymal tissues: superiority of synovium as a cell source. Arthritis and Rheumatism 52 2521-2529. (doi:10.1002/art.21212)
167. Santamaria-MartinezA,BarquineroJ,Barbosa-DesonglesA,HurtadoA,PinosT, Seoane J, PouponMF, Morote J, Reventos J & Munell F 2009 Identification ofmultipotentmesenchymal stromal cells in the reactive stroma of a prostate cancer xenograft by side population analysis. Experimental Cell Research 315 3004-3013. (doi:10.1016/j.yexcr.2009.05.007)
168. Sarkar D, Spencer JA, Phillips JA, Zhao W, Schafer S, Spelke DP, Mortensen LJ, Ruiz JP, Vemula PK, Sridharan R et al. 2011 Engineered cell homing. Blood 118 e184-e191. (doi:10.1182/blood-2010- 10-311464)
169. Sfanos KS & De Marzo AM 2012 Prostate cancer and inflammation: the evidence. Histopathology 60 199-215. (doi:10.1111/j.1365-2559.2011. 04033.x)
170. Shah K 2012 Mesenchymal stem cells engineered for cancer therapy. Advanced Drug Delivery Reviews 64 739-748. (doi:10.1016/j.addr.2011. 06.010)
171. Shimoda M, Mellody KT & Orimo A 2010 Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Seminars in Cell & Developmental Biology 21 19-25. (doi:10.1016/j.semcdb.2009.10.002)
172. da Silva Meirelles L, Chagastelles PC & Nardi NB 2006 Mesenchymal stem cells reside in virtually all post-natal organs and tissues. Journal of Cell Science 119 2204-2213. (doi:10.1242/jcs.02932)
173. Song C, Xiang J, Tang J, Hirst DG, Zhou J, Chan KM & Li G 2011 Thymidine kinase gene modified bone marrow mesenchymal stem cells as vehicles for antitumor therapy. Human Gene Therapy 22 439-449. (doi:10.1089/ hum.2010.116)
174. Spaeth E, Klopp A, Dembinski J, AndreeffM & Marini F 2008 Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Therapy 15 730-738. (doi:10.1038/gt. 2008.39)
175. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC & Moretta L 2006 Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107 1484-1490. (doi:10.1182/blood-2005-07-2775)
176. Stagg J, Pommey S, Eliopoulos N & Galipeau J 2006 Interferon-g-stimulated marrow stromal cells: a new type of nonhematopoietic antigenpresenting cell. Blood 107 2570-2577. (doi:10.1182/blood-2005-07-2793)
177. Stoff-Khalili MA, Rivera AA, Mathis JM, Banerjee NS, Moon AS, Hess A, Rocconi RP, NumnumTM, Everts M, Chow LT et al. 2007 Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Research and Treatment 105 157-167. (doi:10.1007/s10549-006-9449- 8)
178. Strioga M, Viswanathan S, Darinskas A, Slaby O & Michalek J 2012 Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells Stem Cells and Development 21 2724-2752. (doi:10.1089/scd.2011.0722)
179. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ & Andreeff M 2002 Bone marrow-derived mesenchymal stem cells as vehicles for interferon-b delivery into tumors. Cancer Research 62 3603-3608.
180. Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, Champlin RE & Andreeff M 2004 Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. Journal of the National Cancer Institute 96 1593-1603. (doi:10.1093/jnci/djh299)
181. Sun YX, Wang J, Shelburne CE, Lopatin DE, Chinnaiyan AM, Rubin MA, Pienta KJ & Taichman RS 2003 Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. Journal of Cellular Biochemistry 89 462-473. (doi:10.1002/jcb.10522)
182. Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, True L & Nelson PS 2012 Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nature Medicine 18 1359-1368. (doi:10.1038/nm.2890)
183. Sundin M, Ringden O, Sundberg B, Nava S, Gotherstrom C & Le Blanc K 2007 No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica 92 1208-1215. (doi:10.3324/haematol.11446)
184. Takashima Y, Era T, Nakao K, Kondo S, Kasuga M, Smith AG & Nishikawa S 2007 Neuroepithelial cells supply an initial transient wave of MSC differentiation. Cell 129 1377-1388. (doi:10.1016/j.cell.2007.04.028)
185. Technau A, Froelich K, Hagen R & Kleinsasser N 2011 Adipose tissuederived stem cells show both immunogenic and immunosuppressive properties after chondrogenic differentiation. Cytotherapy 13 310-317. (doi:10.3109/ 14653249.2010.504769)
186. Torsvik A, Rosland GV, Svendsen A,Molven A, ImmervollH, McCormack E, Lonning PE, Primon M, Sobala E, Tonn JC et al. 2010 Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track - letter. Cancer Research 70 6393-6396. (doi:10.1158/0008-5472.CAN-10-1305)
187. True LD, Zhang H, Ye M, Huang CY, Nelson PS, von Haller PD, Tjoelker LW, Kim JS, Qian WJ, Smith RD et al. 2010 CD90/THY1 is overexpressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker. Modern Pathology 23 1346-1356. (doi:10.1038/modpathol. 2010.122)
188. Tse WT, Pendleton JD, Beyer WM, Egalka MC & Guinan EC 2003 Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 75 389-397. (doi:10.1097/01.TP.0000045055.63901.A9)
189. Tu Z, Li Q, Bu H & Lin F 2010 Mesenchymal stem cells inhibit complement activation by secreting factor H. Stem Cells and Development 19 1803-1809. (doi:10.1089/scd.2009.0418)
190. Vaday GG, Peehl DM, Kadam PA & Lawrence DM 2006 Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 66 124-134. (doi:10.1002/pros. 20306)
191. Vodyanik MA, Yu J, Zhang X, Tian S, Stewart R, Thomson JA & Slukvin II 2010 A mesoderm-derived precursor for mesenchymal stem and endothelial cells. Cell Stem Cell 7 718-729. (doi:10.1016/j.stem.2010. 11.011)
192. Vogel G 2010 Cell biology. To scientists' dismay, mixed-up cell lines strike again. Science 329 1004. (doi:10.1126/science.329.5995.1004)
193. Wagner W, Wein F, Seckinger A, Frankhauser M, Wirkner U, Krause U, Blake J, Schwager C, Eckstein V, Ansorge W et al. 2005 Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Experimental Hematology 33 1402-1416. (doi:10.1016/j.exphem.2005.07. 003)
194. Wakitani S, Saito T & Caplan AI 1995 Myogenic cells derived from rat bone marrowmesenchymal stem cells exposed to 5-azacytidine. Muscle Nerve 18 1417-1426. (doi:10.1002/mus.880181212)
195. Wang GX, Zhan YA, Hu HL, Wang Y & Fu B 2012 Mesenchymal stem cells modified to express interferon-b inhibit the growth of prostate cancer in a mouse model. Journal of International Medical Research 40 317-327. (doi:10.1177/147323001204000132)
196. Weiss DJ, Casaburi R, Flannery R, Leroux-Williams M& Tashkin DP 2013 A placebo-controlled randomized trial of mesenchymal stem cells in chronic obstructive pulmonary disease. Chest 143 1590-1598. (doi:10.1378/chest.12-2094)
197. Williams SA, Merchant RF, Garrett-Mayer E, Isaacs JT, Buckley JT & Denmeade SR 2007 A prostate-specific antigen-activated channelforming toxin as therapy for prostatic disease. Journal of the National Cancer Institute 99 376-385. (doi:10.1093/jnci/djk065)
198. Woodbury D, Schwarz EJ, Prockop DJ & Black IB 2000 Adult rat and human bone marrow stromal cells differentiate into neurons. Journal of Neuroscience Research 61 364-370. (doi:10.1002/1097- 4547(20000815) 61:4!364::AID-JNR2O3.0.CO;2-C)
199. Ye H, Cheng J, Tang Y, Liu Z, Xu C, Liu Y & Sun Y 2012 Human bone marrow-derived mesenchymal stem cells produced TGFb contributes to progression and metastasis of prostate cancer. Cancer Investigation 30 513-518. (doi:10.3109/07357907.2012.692171)
200. Yin J, Kim JK, Moon JH, Beck S, Piao D, Jin X, Kim SH, Lim YC, Nam DH, You S et al. 2011 hMSC-mediated concurrent delivery of endostatin and carboxylesterase to mouse xenografts suppresses glioma initiation and recurrence. Molecular Therapy 19 1161-1169. (doi:10.1038/mt.2011.28)
201. Zhang W, Walboomers XF, Shi S, Fan M & Jansen JA 2006 Multilineage differentiation potential of stem cells derived from human dental pulp after cryopreservation. Tissue Engineering 12 2813-2823. (doi:10.1089/ ten.2006.12.2813)
202. Zhang X, Xu W, Qian H, Zhu W & Zhang R 2011 Mesenchymal stem cells modified to express lentivirus TNF-a Tumstatin(45-132) inhibit the growth of prostate cancer. Journal of Cellular and Molecular Medicine 15 433-444. (doi:10.1111/j.1582-4934.2009.00920.x)
203. Zhang Z, Lin H, Shi M, Xu R, Fu J, Lv J, Chen L, Lv S, Li Y, Yu S et al. 2012 Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. Journal of Gastroenterology and Hepatology 27 (Suppl 2) 112-120. (doi:10.1111/j. 1440-1746.2011.07024.x)
204. Zhao H & Peehl DM2009 Tumor-promoting phenotype of CD90hi prostate cancer-associated fibroblasts. Prostate 69 991-1000. (doi:10.1002/pros. 20946)
205. Zhukareva V, Obrocka M, Houle JD, Fischer I & Neuhuber B 2010 Secretion profile of human bone marrow stromal cells: donor variability and response to inflammatory stimuli. Cytokine 50 317-321. (doi:10.1016/j. cyto.2010.01.004)
206. Zimmet JM & Hare JM 2005 Emerging role for bone marrow derived mesenchymal stem cells in myocardial regenerative therapy. Basic Research Cardiology 100 471-481. (doi:10.1007/s00395-005-0553-4)
207. Zischek C, Niess H, Ischenko I, Conrad C, Huss R, Jauch KW, Nelson PJ & Bruns C 2009 Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma. Annals of Surgery 250 747-753. (doi:10.1097/SLA.0b013e3181bd62d0)
208. Zolochevska O, Yu G, Gimble JM & Figueiredo ML 2012 Pigment epithelial-derived factor and melanoma differentiation associated gene-7 cytokine gene therapies delivered by adipose-derived stromal/ mesenchymal stem cells are effective in reducing prostate cancer cell growth. Stem Cells and Development 21 1112-1123. (doi:10.1089/scd. 2011.0247)
209. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso ZC, Fraser JK, Benhaim P & Hedrick MH 2002 Human adipose tissue is a source of multipotent stem cells. Molecular Biology of the Cell 13 4279-4295. (doi:10.1091/mbc.E02-02-0105)